The European Commission has given Holoclar®, the first advanced therapy medicinal product (ATMP) containing stem cells, conditional marketing authorisation following a recommendation for approval by the European Medicines Agency.
Holoclar® uses a particular type of eye stem cell, called a limbal stem cell, to repair the cornea after injury; restoring sight.